Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2018

View Archived Issues

Natural and engineered L. lactis as a novel probiotic strategy for cholera protection and diagnosis

Carbetocin is noninferior to oxytocin to prevent postpartum hemorrhage with better heat stability

Encochleated atovaquone formulation evaluated in mouse model of pneumocystis pneumonia

Phase II data presented from ORIENT-1 study of sintilimab in patients with Hodgkin's lymphoma

Phase I/II data for veliparib as add-on therapy for the treatment of HNSCC

Clinical trial authorization granted in U.K. for phase I study of FOR-6219

BMS-986253 well tolerated in phase I study in patients with metastatic or unresectable solid tumors

RND efflux pump inhibitor MBX-4191 developed at Microbiotix for Gram-negative Enterobacteriaceae

Conserved haplotype in SGLT1 is linked with lower risk of dietary hyperglycemia

In vivo evaluation of albumin-binding PSMA analogue [177Lu]HTK-01169 in LNCaP tumor xenograft model

New Era Pharma presents Sgk1 and/or Sgk2 inhibitors

Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news

Celtaxsys divulges new LTA-4 hydrolase inhibitors

Sanofi and Lead Pharma Holding patent RORC modulators

Shenzhen Targetrx Biotechnology presents EGFR mutant inhibitors

Sumitomo Dainippon seeks Japanese approval for thiotepa as pre-HSCT conditioning treatment

Roche initiates phase I study of RO-7172508 in CEA-positive solid tumors

TLR7 agonists presented by Apros Therapeutics

Mitsubishi Tanabe studies MT-7117 in phase II for erythropoietic protoporphyria

Antibe reports secondary endpoint data from phase IIb GI safety study of ATB-346

Immutep submits IND to begin phase II study of eftilagimod with Keytruda

Phase II study of pacritinib in myelofibrosis cleared to continue by IDMC

IDMC clears phase III study of Tedopi in NSCLC to continue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...